A phase 2 study evaluating S 95005 plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004544-18

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for unresectable metastatic colorectal cancer in patients non-eligible for intensive therapy.


Critère d'inclusion

  • Metastatic colorectal cancer